Veru's FC2 Prescription Sales Boost Q2 Revenues

by Vandana Singh, Benzinga Editor

May 12, 2021 8:09 AM | 1 min read | Make a Comment

Veru Inc VERU reported a Q1 EPS loss of ($0.04), which met the analyst consensus estimate. The loss is wider than ($0.01) net loss a year ago.
Sales for the quarter were reported at $13.3 million, up 34% Y/Y, but missed the analyst consensus estimate of $14.29 million.
FC2 prescription net revenues from the U.S. prescription channel climbed 48% Y/Y to $10.3 million.
Gross profit rose 47% Y/Y to $10.9 million, with a gross margin expansion to 82% from 75% last year.
Operating loss was $1.5 million versus $0.3 million last year.
Price Action: VERU shares are up 1.34% at $7.59 during the premarket session on the last check Wednesday.